Zoetis Inc. (NYSE:ZTS) Shares Acquired by Bellecapital International Ltd.

Bellecapital International Ltd. raised its stake in shares of Zoetis Inc. (NYSE:ZTSFree Report) by 5.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,951 shares of the company’s stock after purchasing an additional 1,922 shares during the quarter. Zoetis comprises 1.8% of Bellecapital International Ltd.’s holdings, making the stock its 20th biggest position. Bellecapital International Ltd.’s holdings in Zoetis were worth $7,688,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of ZTS. BOS Asset Management LLC grew its position in Zoetis by 3.2% during the second quarter. BOS Asset Management LLC now owns 1,684 shares of the company’s stock valued at $290,000 after buying an additional 53 shares during the period. Enterprise Financial Services Corp lifted its stake in shares of Zoetis by 2.3% in the first quarter. Enterprise Financial Services Corp now owns 2,446 shares of the company’s stock worth $407,000 after buying an additional 55 shares in the last quarter. CreativeOne Wealth LLC increased its position in Zoetis by 0.4% during the second quarter. CreativeOne Wealth LLC now owns 12,833 shares of the company’s stock worth $2,210,000 after purchasing an additional 57 shares during the last quarter. MJP Associates Inc. ADV increased its position in Zoetis by 4.8% during the third quarter. MJP Associates Inc. ADV now owns 1,275 shares of the company’s stock worth $222,000 after purchasing an additional 58 shares during the last quarter. Finally, TFC Financial Management Inc. increased its position in Zoetis by 3.3% during the third quarter. TFC Financial Management Inc. now owns 1,918 shares of the company’s stock worth $334,000 after purchasing an additional 61 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Barclays lifted their price target on shares of Zoetis from $255.00 to $260.00 and gave the company an “overweight” rating in a research report on Wednesday, February 14th. BNP Paribas started coverage on shares of Zoetis in a research report on Thursday, December 7th. They issued an “outperform” rating and a $237.00 price target for the company. Piper Sandler boosted their price objective on shares of Zoetis from $215.00 to $220.00 and gave the company an “overweight” rating in a research note on Tuesday, February 20th. The Goldman Sachs Group boosted their price objective on shares of Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. Finally, Stifel Nicolaus boosted their price objective on shares of Zoetis from $195.00 to $215.00 and gave the company a “buy” rating in a research note on Friday, January 12th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $224.33.

Check Out Our Latest Report on ZTS

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 363 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $197.74, for a total value of $71,779.62. Following the transaction, the executive vice president now directly owns 20,417 shares in the company, valued at approximately $4,037,257.58. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last ninety days, insiders have sold 2,209 shares of company stock worth $408,453. Corporate insiders own 0.15% of the company’s stock.

Zoetis Stock Performance

NYSE:ZTS opened at $169.21 on Monday. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a fifty-two week low of $151.03 and a fifty-two week high of $201.92. The stock has a market cap of $77.39 billion, a PE ratio of 33.37, a price-to-earnings-growth ratio of 2.58 and a beta of 0.85. The firm’s fifty day simple moving average is $185.10 and its 200-day simple moving average is $181.99.

Zoetis (NYSE:ZTSGet Free Report) last posted its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The company had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.19 billion. During the same period last year, the company earned $1.15 earnings per share. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. Analysts expect that Zoetis Inc. will post 5.8 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be given a $0.432 dividend. The ex-dividend date is Thursday, April 18th. This represents a $1.73 annualized dividend and a dividend yield of 1.02%. Zoetis’s dividend payout ratio is presently 34.12%.

About Zoetis

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

See Also

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.